Last updated on April 18, 2014 at 1:21 EDT

Latest Brodalumab Stories

2013-10-03 00:20:13

THOUSAND OAKS, Calif. and GAITHERSBURG, Md., Oct. 3, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca (AZN), with its biologics research and development arm MedImmune, today announced the upcoming presentation of several key studies evaluating brodalumab, a human monoclonal antibody targeting the interleukin-17 (IL-17) receptor, for the treatment of moderate to severe psoriasis at the 22(nd) Congress of the European Academy of Dermatology and Venereology (EADV) in Istanbul, Oct....

2012-03-28 10:23:16

THOUSAND OAKS, Calif., March 28, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that results from a Phase 2 trial evaluating the safety and efficacy of brodalumab (formerly AMG 827) in 198 patients with moderate to severe plaque psoriasis were published in the New England Journal of Medicine. The 12-week, dose-ranging study achieved its primary endpoint with the mean percentage improvement in psoriasis area and severity index (PASI) score higher in all brodalumab groups compared to...